Impact of disease duration and beta cell reserve on the efficacy of iGlarLixi in patients with type 2 diabetes: the LixiLan-G trialS. Del Prato,J. P. Frias,L. Blonde, V. R. Aroda, N. Shehadeh,R. Henry,A. Saremi,T. Dex,E. Niemoeller, E. Souhami,M. Liu,J. RosenstockDIABETOLOGIA(2019)引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要